HGCO19: mRNA Vaccine
The novel mRNA vaccine candidate, HGCO19 has been developed by Pune-based biotechnology company Gennova Biopharmaceuticals Ltd. in collaboration with HDT Biot
Conventional vaccines usually contain inactivated disease-causing organisms or proteins made by the pathogen (antigens), which work by mimicking the infectious agent.ech Corporation, USA.
RNA vaccines use a different approach that takes advantage of the process that cells use to make proteins: cells use DNA as the template to make messenger RNA (mRNA) molecules, which are then translated to build proteins.
An RNA vaccine consists of an mRNA strand that codes for a disease-specific antigen.
Once the mRNA strand in the vaccine is inside the body’s cells, the cells use the genetic information to produce the antigen.
This antigen is then displayed on the cell surface, where it is recognized by the immune system.